Aliases & Classifications for Withdrawal Disorder

MalaCards integrated aliases for Withdrawal Disorder:

Name: Withdrawal Disorder 12 15
Withdrawal Syndrome 54 15
Substance Withdrawal Syndrome 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0060001
UMLS 71 C0038587

Summaries for Withdrawal Disorder

Disease Ontology : 12 A substance-related disorder that occurs upon the abrupt discontinuation/separation or a decrease in dosage of the intake of medications, recreational drugs, and alcohol.

MalaCards based summary : Withdrawal Disorder, also known as withdrawal syndrome, is related to heroin dependence and neonatal abstinence syndrome, and has symptoms including seizures, opiate withdrawal symptoms and drug withdrawal symptoms. An important gene associated with Withdrawal Disorder is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Ketorolac and Metoclopramide have been mentioned in the context of this disorder. Affiliated tissues include brain, prostate and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Withdrawal Disorder

Diseases related to Withdrawal Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 277)
# Related Disease Score Top Affiliating Genes
1 heroin dependence 31.9 PDYN OPRM1 OPRD1 DRD2 DRD1
2 neonatal abstinence syndrome 31.7 PNOC OPRM1 OPRL1 OPRK1 OPRD1
3 alcohol use disorder 30.5 OPRM1 DRD2 DRD1 CRH
4 chronic pain 30.3 OPRM1 CNR1
5 opiate dependence 30.2 POMC PENK PDYN OPRM1 OPRL1 OPRK1
6 opioid addiction 30.1 PNOC OPRM1 OPRK1 OPRD1 DRD2
7 personality disorder 30.0 DRD2 CRHR1 CRH
8 polysubstance abuse 30.0 DRD2 CNR1
9 motion sickness 29.9 POMC OPRM1 FOS CNR1
10 bulimia nervosa 29.8 POMC DRD2 CRH
11 morphine dependence 29.8 PENK PDYN OPRM1 OPRL1 OPRK1 OPRD1
12 eating disorder 29.6 POMC OPRM1 DRD2 CRH CNR1
13 generalized anxiety disorder 29.6 TSPO DRD2 CRHR1
14 borderline personality disorder 29.5 DRD2 CRHR1 CRH
15 restless legs syndrome 29.4 POMC GABRR3 DRD2 DRD1
16 psychotic disorder 29.4 PDYN OPRM1 DRD2 DRD1 CNR1
17 tobacco addiction 29.3 PDYN OPRM1 DRD2 DRD1 CRHR1 CNR1
18 constipation 29.3 PDYN OPRM1 OPRL1 OPRK1 OPRD1 CNR1
19 mood disorder 29.2 POMC DRD2 DRD1 CRHR1 CRH
20 attention deficit-hyperactivity disorder 29.2 TSPO OPRM1 FOS DRD2 DRD1
21 parkinson disease, late-onset 28.8 TSPO PENK PDYN OPRD1 DRD2 DRD1
22 panic disorder 28.6 TSPO POMC OPRL1 DRD2 DRD1 CRHR1
23 pain agnosia 28.6 POMC PNOC PENK PDYN OPRM1 OPRL1
24 body mass index quantitative trait locus 11 28.5 POMC FOS DRD2 CRHR1 CRH CNR1
25 cocaine dependence 28.4 POMC PDYN OPRM1 OPRK1 OPRD1 DRD2
26 alcohol dependence 28.3 TSPO POMC PNOC PDYN OPRM1 OPRL1
27 substance abuse 28.1 PDYN OPRM1 OPRL1 OPRK1 OPRD1 DRD2
28 anxiety 28.0 TSPO POMC PNOC PDYN OPRM1 OPRL1
29 substance dependence 28.0 POMC PDYN OPRM1 OPRK1 OPRD1 DRD2
30 migraine with or without aura 1 27.5 POMC PNOC OPRM1 OPRL1 OPRK1 OPRD1
31 drug dependence 27.4 POMC PNOC PENK PDYN OPRM1 OPRL1
32 barbiturate dependence 11.4
33 subacute delirium 10.6
34 prostate leiomyoma 10.6 KLK3 AR
35 tremor 10.5
36 cyclic vomiting syndrome 10.5 OPRM1 CNR1
37 submandibular gland cancer 10.5 KLK3 AR
38 prostatic acinar adenocarcinoma 10.5 KLK3 AR
39 uremic pruritus 10.5 OPRK1 CNR1
40 acth-dependent cushing syndrome 10.4 POMC CRH
41 prostate adenoid cystic carcinoma 10.4 POMC KLK3 AR
42 prostate neuroendocrine neoplasm 10.4 KLK3 AR
43 autonomic nervous system disease 10.4 OPRM1 OPRL1 OPRD1
44 somatoform disorder 10.4 OPRM1 OPRL1 OPRD1
45 ileus 10.4 POMC OPRM1 CRH
46 hypoadrenalism 10.4 POMC CRH
47 sex development disorder 10.4 POMC KLK3 AR
48 pituitary infarct 10.3 POMC CRH
49 hallucinogen dependence 10.3 OPRM1 DRD2 CNR1
50 tuberculous epididymitis 10.3 POMC KLK3

Graphical network of the top 20 diseases related to Withdrawal Disorder:



Diseases related to Withdrawal Disorder

Symptoms & Phenotypes for Withdrawal Disorder

UMLS symptoms related to Withdrawal Disorder:


seizures, opiate withdrawal symptoms, drug withdrawal symptoms, withdrawal symptoms

MGI Mouse Phenotypes related to Withdrawal Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 AR CNR1 CRH CRHR1 DRD1 DRD2
2 homeostasis/metabolism MP:0005376 10.22 AR CNR1 CRH CRHR1 DRD1 DRD2
3 growth/size/body region MP:0005378 10.15 AR CNR1 CRH DRD1 DRD2 FOS
4 adipose tissue MP:0005375 10.13 AR CNR1 CRH DRD1 DRD2 FOS
5 endocrine/exocrine gland MP:0005379 10.1 AR CRH CRHR1 DRD2 FOS OPRK1
6 integument MP:0010771 10.1 AR CNR1 CRH DRD1 DRD2 FOS
7 nervous system MP:0003631 10 AR CNR1 CRH CRHR1 DRD1 DRD2
8 digestive/alimentary MP:0005381 9.98 AR CNR1 DRD1 DRD2 OPRK1 OPRM1
9 no phenotypic analysis MP:0003012 9.61 CNR1 CRH CRHR1 DRD2 OPRD1 OPRM1
10 normal MP:0002873 9.36 AR CNR1 CRH CRHR1 DRD1 DRD2

Drugs & Therapeutics for Withdrawal Disorder

Drugs for Withdrawal Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 240)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
2
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
3
Loperamide Approved Phase 4 53179-11-6 3955
4
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
5
Lofexidine Approved, Investigational Phase 4 31036-80-3 30668
6
Tetrabenazine Approved, Investigational Phase 4 58-46-8 6018
7
Oxazepam Approved Phase 4 604-75-1 4616
8
Sodium oxybate Approved Phase 4 502-85-2 5360545
9
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
10
Flumazenil Approved Phase 4 78755-81-4 3373
11
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
12
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
13
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
14
Haloperidol Approved Phase 4 52-86-8 3559
15
Morphine Approved, Investigational Phase 4 57-27-2 5288826
16
Nicotine Approved Phase 4 54-11-5 942 89594
17
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
18
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
19
Chlordiazepoxide Approved, Illicit, Investigational Phase 4 58-25-3 2712
20
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
21
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
22
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
23
Clonidine Approved Phase 4 4205-90-7 2803
24
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
25
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
26
tannic acid Approved Phase 4 1401-55-4
27
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
28
Esmolol Approved Phase 4 81147-92-4, 103598-03-4 59768
29
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
30
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
31
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
32 Adjuvants, Immunologic Phase 4
33 Anti-Inflammatory Agents, Non-Steroidal Phase 4
34 Dopamine Antagonists Phase 4
35 Dopamine D2 Receptor Antagonists Phase 4
36 Cyclooxygenase Inhibitors Phase 4
37 Ketorolac Tromethamine Phase 4
38 phenazepam Phase 4 40113
39 Antidiarrheals Phase 4
40 Liver Extracts Phase 4
41 Adjuvants, Anesthesia Phase 4
42 Neuromuscular Agents Phase 4
43 Opiate Alkaloids Phase 4
44 Narcotic Antagonists Phase 4
45 Central Nervous System Stimulants Phase 4
46 Pharmaceutical Solutions Phase 4
47 Detox adjuvant Phase 4
48 Sodium Channel Blockers Phase 4
49 Diuretics, Potassium Sparing Phase 4
50 Antidotes Phase 4

Interventional clinical trials:

(show top 50) (show all 164)
# Name Status NCT ID Phase Drugs
1 Randomized Clinical Trial of Pregabalin for Opioid Withdrawal Syndrome Unknown status NCT03017430 Phase 4 Pregabalin;Clonidine;Doxylamin;Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
2 Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
3 A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Completed NCT03698331 Phase 4 Valbenazine;Placebo oral capsule
4 The Gamma Hydroxybutyric Acid in Alcohol-dependence Treatment Efficacy (GATE) I Trial: a Comparative Study Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome Completed NCT02090504 Phase 4 Sodium Oxybate (SMO);Oxazepam
5 A Behavioral Assessment of Electronic Cigarettes in Reducing Cue- and Withdrawal-induced Craving in Daily Dependent Smokers Completed NCT02108626 Phase 4 Nicotine;Placebo
6 Nicotine Replacement Therapy in the Intensive Care Unit: a Randomized, Controlled Pilot Study Completed NCT01362959 Phase 4 Transdermal nicotine patch
7 Acute Drug Withdrawal in a General Medical Setting Completed NCT00249366 Phase 4 Lorazepam (drug);Lorazepam
8 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
9 Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán Completed NCT03877120 Phase 4 Dexmedetomidine 0.004 MG/ML;Diazepam Injectable Solution
10 Carbamazepine and Lorazepam in Outpatient Detoxification Completed NCT00000441 Phase 4 lorazepam (Ativan);carbamazepine (Tegretol)
11 Comparison of Chlordiazepoxide and Gabapentin for Outpatient Alcohol Detoxification Treatment Completed NCT01573052 Phase 4 Chlordiazepoxide;Gabapentin
12 Effect of Flumazenil on Hypoactive Delirium Secondary to Benzodiazepine Toxicity in the ICU Completed NCT02899156 Phase 4 Flumazenil;Placebo
13 Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis Completed NCT01837433 Phase 4 Prednisone 1 week;Prednisone 6 weeks
14 Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal Syndrome in the ICU: a Randomised Controlled Study Completed NCT02496650 Phase 4 Dexmedetomidine
15 A Double-blind Randomised Controlled Clinical Trial of Lofexidine Versus Diazepam in the Management of the Opioid Withdrawal Syndrome During Inpatient Detoxification in Singapore Completed NCT01675648 Phase 4 Lofexidine;Diazepam;Placebo for Lofexidine;Placebo for Diazepam
16 A Double-Blind, Placebo-Controlled Trial of Reward Responsivity During Nicotine Withdrawal in Smokers With Schizophrenia and Normal Controls Completed NCT00373126 Phase 4 transdermal nicotine patch
17 A Prospective Randomized Controlled Open Label Trial of Symptom-triggered Benzodiazepine Versus Fixed-dose Gabapentin for Alcohol Withdrawal Syndrome Recruiting NCT03012815 Phase 4 Gabapentin;Benzodiazepines;Divalproex Sodium
18 Varenicline OTC Trial on Efficacy and Safety Recruiting NCT03557294 Phase 4 1.0mg Varenicline b.i.d.;0.5mg Varenicline b.i.d.;0.0mg placebo Varenicline b.i.d.
19 Prospective Assessment of Valproate on Ethanol Withdrawal Recruiting NCT03235531 Phase 4 Valproate;Lorazepam
20 Efficacy and Safety of the Administration of the Passiflora Extract for Benzodiazepine Withdrawal in Institutionalized Older Adults: Clinical Trial Phase III Recruiting NCT03780595 Phase 4 Passiflora incarnata;Control
21 Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy Recruiting NCT03092011 Phase 4 Clonidine;Morphine Sulfate
22 Using Imaging to Assess Effects of THC on Brain Activity Recruiting NCT03655717 Phase 4 Dronabinol;Ethanol;Placebo Dronabinol;Placebo Ethanol
23 Assessment of NADA Acupuncture for Treatment of Withdrawal Symptoms During Gradual Opioid Withdrawal in Chronic Pain Patients Not yet recruiting NCT03397212 Phase 4
24 Phenobarbital Versus Ativan for Refractory Alcohol Withdrawal Treatment in the Intensive Care Unit Not yet recruiting NCT04156464 Phase 4 Phenobarbital;Lorazepam
25 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) Terminated NCT01362205 Phase 4 Dexmedetomidine;Placebos
26 Evaluation of Pregabalin's Abuse Liability and Its Effects on Benzodiazepine Withdrawal Symptoms in Inpatients Undergoing Medically Assisted Benzodiazepine Withdrawal Terminated NCT02423018 Phase 4 Pregabalin;Placebo
27 Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol: A Study Comparing the Post Op Continuation of the Preoperative Oral Dose Beta Blockers to Intravenous Esmolol Titrated to a Target Heart Rate (HR) Terminated NCT01404767 Phase 4 Esmolol;Metoprolol
28 A Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Phenobarbital and Ketamine Adjunctive Therapies in the Treatment of Alcohol Withdrawal Syndrome Withdrawn NCT03788889 Phase 4 Ketamine;Phenobarbital;Lorazepam;Placebo A;Placebo B
29 Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal Completed NCT00980044 Phase 2, Phase 3 Tramadol;Placebo
30 Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome [Sicherheit Und Wirksamkeit Von Levetiracetam (Keppra) für Die Behandlung Des stationären Alkoholentzugsyndroms] Completed NCT00146471 Phase 3 Levetiracetam;Placebo
31 Comparison of a Fixed-Schedule Therapy Versus a Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome in Medical Out-Patients Completed NCT00136617 Phase 3 chlordiazepoxide
32 A Phase 3, Open-Label, Safety Study of Lofexidine Completed NCT02363998 Phase 3 Lofexidine
33 Buprenorphine/Naloxone Versus Clonidine For Out-patient Opiate Detoxification Completed NCT00032968 Phase 3 Buprenorphine/naloxone
34 Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification Completed NCT00032955 Phase 3 Buprenorphine/naloxone
35 A Randomized, Double-Blind, Multiple-Dose, Parallel Group Study to Evaluate the Potential of Withdrawal Effects Following Administration of Oxycodone/Naltrexone Capsules and Oxycodone in Methadone-Maintained Opioid-Dependent Subjects Completed NCT02391571 Phase 3 Oxycodone/Naltrexone Capsules;Oxycodone;Placebo
36 Pharmacogenetics, Emotional Reactivity and Smoking Cessation: Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal Completed NCT00664404 Phase 3
37 Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14) Completed NCT01863186 Phase 3 Lofexidine HCl;Placebo;Open Label Lofexidine HCL
38 Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers Completed NCT00018174 Phase 3 Fluoxetine;Placebo
39 The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels Completed NCT03097484 Phase 3 lavender and chamomile essential oils
40 Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms Completed NCT00202514 Phase 2, Phase 3 divalproex sodium extended release
41 Multicenter Randomized Placebo Controlled Trial Assessing the Efficacy of Oral Adjuvant Magnesium Supplementation in the Treatment of Alcohol Withdrawal Syndrome Recruiting NCT03033823 Phase 3 Magnesium;Placebo Oral Tablet
42 Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU: Study Protocol for a Randomised Controlled Against Placebo Trial Recruiting NCT02723383 Phase 3 BACLOFEN;PLACEBO
43 NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): Infant Neurodevelopmental Outcomes (INO) Sub-study Not yet recruiting NCT03911739 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
44 NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): a Pragmatic Randomized Trial Comparing Extended-release and Daily Buprenorphine Formulations: Conceptual Model Assessments (CMA) Sub-study Not yet recruiting NCT03911466 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
45 Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): a Pragmatic Randomized Trial Comparing Extended-release and Daily Buprenorphine Formulations Not yet recruiting NCT03918850 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
46 Preventing Alcohol Withdrawal Syndrome With Oral Baclofen: A Randomized, Placebo Controlled Trial Terminated NCT02052440 Phase 3 Baclofen;Placebo
47 ASSESSMENT OF THE SAFETY AND BENEFIT OF PROSPECTIVE IMMUNOSUPPRESSIVE DRUG WITHDRAWAL IN LIVER TRANSPLANTATION AND PREDICTION OF OPERATIONAL TOLERANCE Unknown status NCT00647283 Phase 2
48 Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study Unknown status NCT02249026 Phase 1, Phase 2 BZDs + opiate exposure treated with BPN;Opiates exposure treated with BPN
49 The Effects of One-Time Pregnenolone, DHEA, Or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers Completed NCT00900900 Phase 2 Placebo
50 Effects of Dynorphin 1-13 on Heroin Addiction Completed NCT00000244 Phase 2 Dynorphin 1 - 13

Search NIH Clinical Center for Withdrawal Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carbamazepine
Clonidine
CLONIDINE HCL PWDR
Clonidine Hydrochloride
Haloperidol
haloperidol decanoate
Haloperidol lactate
Hydroxyzine
Hydroxyzine Hydrochloride
Hydroxyzine Pamoate
Lorazepam
Perphenazine
Procaine
Procaine hydrochloride

Genetic Tests for Withdrawal Disorder

Anatomical Context for Withdrawal Disorder

MalaCards organs/tissues related to Withdrawal Disorder:

40
Brain, Prostate, Heart, Liver, Pituitary, Myeloid, Cortex

Publications for Withdrawal Disorder

Articles related to Withdrawal Disorder:

(show top 50) (show all 3982)
# Title Authors PMID Year
1
Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. 54 61
17302569 2007
2
Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. 54 61
16037707 2005
3
Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. 54 61
15166229 2004
4
3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. 54 61
12672951 2003
5
Behavioral effects of potentiated antibodies to morphine and mu-opioid receptors during withdrawal syndrome. 54 61
12949640 2003
6
Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. 54 61
11803262 2002
7
Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy. 54 61
12083956 2001
8
Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. 54 61
11085345 2000
9
Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression. 54 61
9634122 1998
10
Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. 54 61
9636157 1998
11
[Molecular biological aspect]. 54 61
9617316 1998
12
Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate. 54 61
9743699 1998
13
[An equivalent of anti-androgen withdrawal syndrome: decrease of prostate specific antigen and clinical response to estramustine phosphate withdrawal]. 54 61
9180872 1997
14
The antiandrogen withdrawal syndrome. 54 61
9144890 1997
15
Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. 54 61
8827083 1996
16
Hyperadrenergic state following acute withdrawal from clonidine used at supratherapeutic doses. 54 61
8726097 1996
17
Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. 54 61
7510915 1994
18
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. 54 61
7679759 1993
19
alpha N-acetyl human beta-endorphin-(1-31) alleviates the morphine withdrawal syndrome in rodents: a comparative study with clonidine. 54 61
1608292 1992
20
Reversible neurologic abnormalities associated with prolonged intravenous midazolam and fentanyl administration. 54 61
1919899 1991
21
m-Trifluoromethyl-diphenyl diselenide (m-CF3-PhSe)2 modulates the hippocampal neurotoxic adaptations and abolishes a depressive-like phenotype in a short-term morphine withdrawal in mice. 61
31689445 2020
22
Modeling acquired resistance to the second-generation androgen receptor antagonist enzalutamide in the TRAMP model of prostate cancer. 61
32029552 2020
23
Abrupt withdrawal of cannabidiol (CBD): A randomized trial. 61
32036242 2020
24
Avoiding NICU Transfers for Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS): A Quality Improvement Initiative to Manage NOWS on the Mother-baby Unit. 61
31972766 2020
25
Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of simvastatin in mice: Without tolerance and withdrawal syndrome. 61
31669314 2020
26
Survey of analgesia and sedation in pediatric intensive care units in Japan. 61
31910495 2020
27
Neuronal nicotinic acetylcholine receptors mediate ∆9 -THC dependence: Mouse and human studies. 61
30378732 2020
28
Molecular and Regulatory Mechanisms of Desensitization and Resensitization of GABAA Receptors with a Special Reference to Propofol/Barbiturate. 61
31952324 2020
29
Breastfeeding Motivators and Barriers in Women Receiving Medications for Opioid Use Disorder. 61
31692370 2020
30
Efficacy of lofexidine for mitigating opioid withdrawal symptoms: results from two randomized, placebo-controlled trials. 61
32002194 2020
31
Genomics and Neonatal Opioid Withdrawal Syndrome. 61
31668675 2020
32
The Role of the Central Amygdala in Alcohol Dependence. 61
31988201 2020
33
Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system. 61
31732295 2020
34
Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis. 61
31534081 2020
35
Fixed-dose gabapentin augmentation in the treatment of alcohol withdrawal syndrome: a retrospective, open-label study. 61
31490712 2020
36
Assessment and treatment of the withdrawal syndrome in paediatric intensive care units: Systematic review. 61
32000360 2020
37
Sedative and Analgesic Drug Rotation Protocol in Critically Ill Children With Prolonged Sedation: Evaluation of Implementation and Efficacy to Reduce Withdrawal Syndrome. 61
31261229 2019
38
Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects. 61
31876433 2019
39
Efficacy and safety of dexmedetomidine for prevention of withdrawal syndrome in the pediatric intensive care unit: protocol for an adaptive, multicenter, randomized, double-blind, placebo-controlled, non-profit clinical trial. 61
31829274 2019
40
Diphenhydramine Use Disorder and Complicated Withdrawal in a Palliative Care Patient. 61
31808723 2019
41
Gestational buprenorphine exposure: Effects on pregnancy, development, neonatal opioid withdrawal syndrome, and behavior in a translational rodent model. 61
31706250 2019
42
Lorazepam versus chlordiazepoxide for the treatment of alcohol withdrawal syndrome and prevention of delirium tremens in general medicine ward patients. 61
31176787 2019
43
Research and policy priorities for addressing prenatal exposure to opioids in Alaska. 61
31020919 2019
44
Use of psychoactive substances in women in outpatient treatment. 61
31851251 2019
45
Adjunctive memantine for opioid use disorder treatment: A systematic review. 61
31757263 2019
46
Cognitive interference as a possible therapeutic strategy to prevent expression of benzodiazepine withdrawal. 61
31299121 2019
47
Intrathecal baclofen as emergency treatment alleviates severe intractable autonomic dysreflexia in cervical spinal cord injury. 61
31815605 2019
48
Hypertensive Urgency and Emergency in Alcohol Withdrawal: A Literature Review. 61
31846238 2019
49
Effect of lofexidine on cardiac repolarization during treatment of opioid withdrawal. 61
31606589 2019
50
Opioid and Benzodiazepine Iatrogenic Withdrawal Syndrome in Patients in the Intensive Care Unit. 61
31951658 2019

Variations for Withdrawal Disorder

Expression for Withdrawal Disorder

Search GEO for disease gene expression data for Withdrawal Disorder.

Pathways for Withdrawal Disorder

Pathways related to Withdrawal Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.55 POMC PNOC PENK PDYN OPRM1 OPRL1
2
Show member pathways
12.78 TSPO POMC PNOC PENK PDYN OPRM1
3
Show member pathways
12.73 POMC FOS DRD2 DRD1 CRHR1 CRH
4 12.15 POMC FOS DRD2 DRD1
6 11.9 POMC DRD1 CRHR1 CRH
7
Show member pathways
11.78 PDYN FOS DRD2 DRD1
8 11.73 POMC OPRM1 OPRD1 FOS
9 11.66 NCOA4 KLK3 AR
10 11.53 POMC FOS CRHR1 CRH
11 11.41 NCOA4 KLK3 AR
12
Show member pathways
11.3 KLK3 FOS AR
13 10.18 POMC CRHR1 CRH

GO Terms for Withdrawal Disorder

Cellular components related to Withdrawal Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.25 PNOC PENK PDYN OPRM1 OPRL1 OPRK1
2 integral component of plasma membrane GO:0005887 9.81 OPRM1 OPRL1 OPRK1 OPRD1 GABRR3 DRD2
3 dendrite GO:0030425 9.73 PNOC PENK PDYN OPRM1 DRD2 DRD1
4 perikaryon GO:0043204 9.67 PENK OPRM1 DRD2 CRH
5 GABA-ergic synapse GO:0098982 9.63 DRD2 DRD1 CNR1
6 integral component of postsynaptic membrane GO:0099055 9.58 OPRM1 DRD2 DRD1
7 integral component of presynaptic membrane GO:0099056 9.35 OPRM1 OPRD1 DRD2 DRD1 CNR1
8 spine apparatus GO:0097444 9.32 OPRM1 OPRD1
9 axon terminus GO:0043679 9.02 PNOC PENK PDYN OPRD1 DRD2

Biological processes related to Withdrawal Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 10.01 POMC OPRM1 OPRD1 FOS
2 response to drug GO:0042493 10.01 TSPO FOS DRD2 DRD1 CRH
3 signal transduction GO:0007165 10 POMC PNOC PENK OPRM1 OPRL1 OPRK1
4 chemical synaptic transmission GO:0007268 9.97 PNOC PENK PDYN OPRK1 GABRR3 CRH
5 aging GO:0007568 9.96 TSPO PENK FOS CNR1
6 response to lipopolysaccharide GO:0032496 9.94 PENK OPRM1 FOS CNR1
7 response to toxic substance GO:0009636 9.88 PENK FOS DRD2
8 response to ethanol GO:0045471 9.88 PENK OPRM1 DRD2 CRH CNR1
9 female pregnancy GO:0007565 9.86 PNOC FOS CRHR1 CRH
10 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.84 OPRM1 OPRK1 OPRD1
11 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.83 DRD2 DRD1 CNR1
12 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.83 OPRM1 OPRD1 DRD1 CNR1
13 locomotory behavior GO:0007626 9.83 PENK OPRM1 OPRK1 DRD2 DRD1
14 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.81 OPRM1 OPRL1 OPRK1 OPRD1
15 response to nicotine GO:0035094 9.8 PENK DRD2 CNR1
16 sensory perception of pain GO:0019233 9.8 PENK OPRM1 OPRL1 OPRK1 CNR1
17 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.79 OPRL1 DRD2 DRD1
18 regulation of sensory perception of pain GO:0051930 9.78 OPRM1 OPRL1 OPRD1
19 associative learning GO:0008306 9.77 DRD2 DRD1 CRH
20 negative regulation of blood pressure GO:0045776 9.77 OPRL1 DRD2 CNR1
21 response to cocaine GO:0042220 9.77 OPRM1 DRD2 DRD1 CRH CNR1
22 G protein-coupled receptor signaling pathway GO:0007186 9.77 POMC PNOC PENK PDYN OPRM1 OPRL1
23 response to morphine GO:0043278 9.76 PENK OPRM1 DRD2 CNR1
24 eating behavior GO:0042755 9.74 OPRM1 OPRL1 OPRD1
25 synaptic transmission, dopaminergic GO:0001963 9.72 DRD2 DRD1 CRH
26 estrous cycle GO:0044849 9.71 OPRM1 OPRL1
27 startle response GO:0001964 9.71 PENK DRD2
28 prepulse inhibition GO:0060134 9.71 DRD2 DRD1
29 behavioral response to ethanol GO:0048149 9.71 OPRM1 DRD2
30 negative regulation of voltage-gated calcium channel activity GO:1901386 9.71 OPRL1 DRD2 CRHR1
31 dopamine metabolic process GO:0042417 9.7 DRD2 DRD1
32 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.7 DRD2 DRD1
33 positive regulation of urine volume GO:0035810 9.7 OPRL1 DRD2
34 regulation of synaptic transmission, GABAergic GO:0032228 9.69 DRD2 CNR1
35 grooming behavior GO:0007625 9.69 DRD2 DRD1
36 regulation of systemic arterial blood pressure GO:0003073 9.69 KLK3 AR
37 striatum development GO:0021756 9.68 DRD2 DRD1
38 locomotory exploration behavior GO:0035641 9.68 PENK CRH
39 behavior GO:0007610 9.68 OPRL1 OPRK1
40 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.68 OPRM1 DRD1
41 peristalsis GO:0030432 9.67 DRD2 DRD1
42 parturition GO:0007567 9.67 CRHR1 CRH
43 positive regulation of behavioral fear response GO:2000987 9.66 PENK CRH
44 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0106072 9.65 OPRM1 OPRL1
45 cerebral cortex GABAergic interneuron migration GO:0021853 9.65 DRD2 DRD1
46 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.64 DRD2 DRD1
47 conditioned taste aversion GO:0001661 9.63 FOS DRD1
48 negative regulation of dopamine secretion GO:0033602 9.62 DRD2 CNR1
49 opioid receptor signaling pathway GO:0038003 9.62 OPRM1 OPRL1 OPRK1 OPRD1
50 regulation of corticosterone secretion GO:2000852 9.58 POMC CRHR1

Molecular functions related to Withdrawal Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.92 OPRM1 OPRL1 OPRK1 OPRD1 DRD2 DRD1
2 peptide binding GO:0042277 9.67 OPRM1 OPRL1 OPRK1 OPRD1
3 neuropeptide hormone activity GO:0005184 9.58 PNOC PENK CRH
4 dopamine binding GO:0035240 9.48 DRD2 DRD1
5 dopamine neurotransmitter receptor activity GO:0004952 9.46 DRD2 DRD1
6 androgen binding GO:0005497 9.43 TSPO AR
7 opioid receptor binding GO:0031628 9.43 PNOC PENK PDYN
8 opioid peptide activity GO:0001515 9.33 PNOC PENK PDYN
9 neuropeptide binding GO:0042923 9.26 OPRM1 OPRL1 OPRK1 OPRD1
10 opioid receptor activity GO:0004985 8.92 OPRM1 OPRL1 OPRK1 OPRD1

Sources for Withdrawal Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....